Goossens Herman, Grabein Béatrice
Department of Microbiology, University Hospital Antwerp, Edegem-Antwerp, B-2650, Belgium.
Diagn Microbiol Infect Dis. 2005 Dec;53(4):257-64. doi: 10.1016/j.diagmicrobio.2005.10.001.
This article presents prevalence and susceptibility data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program in Europe (1997-2004) and the United States (1999-2004) for Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBL) and/or AmpC beta-lactamases. For ESBL-producing isolates, the prevalence of Escherichia coli and Klebsiella spp. in Europe and Enterobacter spp. in the United States increased over time. For AmpC-producing isolates, the prevalence of Enterobacter spp. and Citrobacter spp. decreased over time in Europe and the United States, respectively. Compared with other antimicrobial agents, meropenem and imipenem had greatest activity against ESBL-producing E. coli and Klebsiella spp. in both Europe (96.9-100.0%) and the United States (100.0%). Such activity was also found for AmpC-producing Enterobacteriaceae in Europe (50.0-100.0%), and Enterobacter spp. and Citrobacter spp. from the United States (100.0% for both). The continued efficacy of carbapenems such as meropenem confirms that these remain first-line agents for treatment of nosocomial infections caused by Enterobacteriaceae-producing ESBL or AmpC beta-lactamases.
本文展示了欧洲（1997 - 2004年）和美（1999 - 2004年）美罗培南年度药敏试验信息收集（MYSTIC）项目中，产超广谱β-内酰胺酶（ESBL）和/或AmpCβ-内酰胺酶的肠杆菌科细菌的流行率和药敏数据。对于产ESBL的分离株，欧洲的大肠杆菌和克雷伯菌属以及美国的肠杆菌属的流行率随时间增加。对于产AmpC的分离株，欧洲的肠杆菌属和美国的柠檬酸杆菌属的流行率分别随时间下降。与其他抗菌药物相比，美罗培南和亚胺培南对欧洲（96.9 - 100.0%）和美（100.0%）产ESBL的大肠杆菌和克雷伯菌属活性最强。在欧洲，这种活性也见于产AmpC的肠杆菌科细菌（50.0 - 100.0%），以及美国的肠杆菌属和柠檬酸杆菌属（两者均为100.0%）。美罗培南等碳青霉烯类药物的持续疗效证实，它们仍然是治疗由产ESBL或AmpCβ-内酰胺酶的肠杆菌科细菌引起的医院感染的一线药物。
